ArticleAnnals of surgical oncology2026
Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundNeoadjuvant therapy (NAT) has become the cornerstone in the treatment of localized pancreatic cancer (LPC), with the goal of downstaging tumors, treating occult metastases, and selecting patients with favorable biology for surgery. Although the benefits of NAT have been well described, real-world data on attrition rates and barriers against proceeding to pancreatectomy are limited.
methodsThis study analyzed LPC patients treated with at least one cycle NAT at a high-volume center (2011-2022). The patients were stratified by radiographic stage (resectable [R], borderline resectable [BR], locally advanced [LA]), or pancreatectomy status. Reasons for attrition during NAT and survival outcomes were evaluated.
resultsAmong 427 LPC patients who received NAT (R, 57 [13%]; BR, 133 [31%]; and LA, 237 [56%]), 182 (43%) underwent pancreatectomy. The overall attrition rate of 57% during NAT was driven by disease progression (21%), persistent inoperability (22%), physiologic decline (11%), loss to follow-up evaluation (2%), and surgery refusal (1%). Attrition rates correlated with stage (R [23%], BR [44%], LA [73%]; p < 0.01). The median overall survival (OS) was significantly longer for the resected patients (30 vs 16 months; p < 0.01) and inversely correlated with stage (R [30 months], BR [21 months], and LA [18 months]; p < 0.01). Overall survival was similar across stages among the resected patients after NAT (R [31 months], BR [27 months], and LA [34 months]; p = 0.66).
conclusionsStage-stratified attrition during NAT remains a significant issue even for patients with R disease. The similar OS across stages for resected patients highlights NAT's role in selecting those most likely to benefit from surgery and underscores the need for strategies to reduce attrition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.